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Objectives. Hypothalamic-Pituitary-Adrenal axis function may be abnormal in rheumatoid arthritis (RA). A pilot study in 7
patients suggested impaired glucocorticoid feedback in some patients after the dexamethasone-corticotrophin releasing hormone
(CRH) test. This study aimed to investigate the dexamethasone-corticotrophin releasing factor test in a larger group of patients
and relate the results to characteristics of the disease. Methods. Outpatients with active RA (≥3 swollen and tender joints and
C-reactive protein > 10mg/L) took dexamethasone (1.5mg) at 23:00hour in the evening. Next day, baseline saliva and plasma
samples were collected, CRH was infused at 11:00hour, and 4 serial blood and saliva samples were collected. Plasma samples were
stored at −80
◦C and a radioimmunoassay performed for saliva and plasma cortisol. Results. All 20 participants showed normal
dexamethasone suppression and mounted no response to the CRH challenge. In samples with measurable cortisol, there was a
strong correlation between saliva and plasma values (r = 0.876, n = 26, P<. 01). Conclusion. No abnormalities were found in
the Dexamethasone-CRH test in RA patients in contrast to a previous pilot study. Salivary cortisol measurement may oﬀer an
alternative noninvasive technique to plasma cortisol in RA patients in future studies.
Copyright © 2009 Eman A. Hasan et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Rheumatoidarthritis(RA)isamultifactorialchronicinﬂam-
matory joint disease that involves secretion of proinﬂam-
matory cytokines such as tumour necrosis factor-α (TNF-
α), interleukin 1 (IL-1), and IL-6 which are associated with
local inﬂammation and a systemic reaction [1, 2]. The
hypothalamic-pituitary-adrenal (HPA) axis and the systemic
sympatheticandadreno-medullary(sympathetic)systemare
the major physiological pathways which mediate responses
to stress, controlled centrally from the hypothalamus and
the brain stem, whose main function is to maintain basal
and stress-related homeostasis [3, 4]. Thus a feedback
system operates through the CNS, the HPA axis and
the hypothalamic-autonomic nervous system (HANS) [5]
Cytokines induce increased release of adreno-corticotrophic
h o r m o n e( A C T H )( a n dh e n c ec o r t i s o l )[ 6, 7] through
production of corticotrophin releasing hormone (CRH) and
arginine vasopressin (AVP) [4, 8]. CRH and AVP exert a
synergistic action on the release of ACTH, and cortisol exerts
a negative feedback action on ACTH and CRH [9]. Because
of the importance of cortisol as an anti-inﬂammatory
compound, HPA integrity and cortisol production in RA
have been extensively investigated. No major defects in the
HPA axis have been reported in RA but subtle abnormalities
have been identiﬁed and it is generally accepted that the HPA
axis response to inﬂammation in RA is inadequate [10].
The corticotrophin releasing hormone (CRH) test was
developedasatechniqueforassessingHPAaxisintegrity,and
its further more sensitive modiﬁcation, the dexamethasone-
corticotrophin-releasing hormone test (Dex-CRH test), has
been used to investigate changes in HPA axis function in
patients with depression [11, 12]. In the Dex-CRH test the
pituitary release of ACTH in response to CRH infusion is
prevented by the prior administration of dexamethasone, a
commonly used therapeutic corticosteroid. The subsequent2 International Journal of Endocrinology
administration of exogenous CRH provides a measure of the
sensitivity of the corticotropes to CRH which in turn reﬂects
the degree of synergy with endogenous AVP release into
the portal blood. Studies in depressed patients have noted
an increased cortisol response to CRH following dexam-
ethasone,suggestingdecreasedcentralfeedback sensitivity to
circulating corticosteroids.
We have previously reported a pilot study using the
Dex-CRH test to investigate possible abnormalities in HPA
axis activity in RA patients, and found that 3 of 7 patients
failed to suppress their cortisol response to CRH after taking
dexamethasone [13]. We did not investigate any underlying
mechanism for this phenomenon but speculated that it may
be a consequence of impaired glucocorticoid feedback in this
subgroup of patients, a phenomenon which may be due to
downregulation of glucocorticoid receptors (GRs) [14]o r
GR polymorphisms [15–17]. Our initial investigation was
limitedtoasmallnumberofpatientswithveryactivedisease.
While suggesting that some patients have disruption in HPA
control, it was not possible in this limited study to relate
this to past or future disease activity. Therefore, the present
study was undertaken to include a larger number of patients
with a range of disease activity, severity, duration, and age,
and with the intention of comparing the subsequent course
of disease in those with and without abnormal Dex-CRH
responses. On the basis of the pilot study, we anticipated
that the present study would reveal a larger number of RA
patients with an early cortisol release from dexamethasone.
Wehypothesisedthatthissubgroupofpatientswoulddisplay
increased disease activity when clinically assessed at 6 and 12
month time points after the study.
As an additional investigation, we also measured salivary
cortisol in RA patients. Saliva sampling has been used as
a non-invasive technique to measure unbound bioactive
levels of cortisol in normal healthy subjects, and in a wide
range of psychological and pathophysiological conditions
[18, 19]. Subtle dysfunctions in basal and stress-induced
cortisol secretion have been reported in RA patients [10, 20]
and salivary sampling would be advantageous for use in
future investigations of HPA axis activity in RA. A strong
positive correlation between blood and salivary cortisol has
been reported in healthy subjects [20, 21]. However, many
patients with RA have secondary Sjogren’s syndrome, which
causes reduced and altered saliva secretion. This may impair
the ability of salivary cortisol concentrations to adequately
reﬂect plasma concentrations. Therefore we investigated the
correlation of plasma and salivary cortisol in RA patients.
2.MaterialsandMethods
2.1. Patients. Outpatients with active RA (≥3s w o l l e na n d
tender joints and C-reactive protein (CRP) > 10mg/L)
were recruited to the study. Participants were selected to be
widelyrepresentativeintermsofage,gender,diseaseseverity,
and duration. Patients that had received glucocorticoid
therapy within 6 weeks prior to the study were excluded, as
were patients on anti-TNF therapy, premenopausal women,
and those taking heparin, vasopressin, or undergoing renal
dialysis. Almost all the patients were taking nonsteroidal
anti-inﬂammatory drugs. Transport and refreshments were
provided. We did not incorporate a healthy control group
into the study design since in our previous study [13].
there was such a large and clearcut diﬀerence between
patient suppressors and nonsuppressors that we felt justiﬁed
in predicting a similar outcome this time. Therefore we
predicted that we would identify two quite distinct patient
groups, the subgroup of patients who demonstrated an early
escape from dexamethasone suppression by mounting a
cortisolresponsetoCRH,andthepatientswhosecortisolwas
suppressed following the DEX-CRH test. This suppressor
group would act as the control group. Given this study
design, and the question it addressed, we considered it
unnecessary, and therefore unethical, to include a control
group of non-RA patients.
2.2. Ethics. Ethical approval was obtained from the Research
Ethics Committee of United Bristol Healthcare NHS Trust
and all participants gave written informed consent.
2.3. Procedure. In addition to their normal medications,
patients were given 1.5mg dexamethasone to take orally at
23:00 hour on the eve of the study. Patients were given
a reminder telephone call approximately one hour before
that time. The following morning, patients were admitted
to the Rheumatology Day Case Unit at 09:30 hour where an
intravenous cannula was inserted, usually in the antecubital
fossa, and ﬂushed with 5mL 0.9% saline. This ﬂush was
repeated after each blood sample aspiration, and the ﬁrst
3mL of each aspiration was discarded to avoid dilution
eﬀects. Baseline blood and salivary samples were taken
at 10:00 and at 10:30 hour. Blood samples were placed
immediately on ice, and quickly transferred to EDTA tubes
for centrifuge, after which plasma was promptly separated,
aliquoted, and stored on dry ice until transfer to a −20
◦C
freezer.Salivarysampleswereobtainedbyaskingthepatients
to dribble into specimen tubes. The samples were stored at
−20
◦C. At 11:00, 100μg human CRH (ClinAlpha, Merck
Chemical Limited, Nottingham, England) reconstituted in
5mL 0.02% HCl in 0.9% saline was infused through the
cannula over 30 seconds. Further blood and salivary samples
were taken at 11:30, 12:00, 12:30 and 13:00 hour. Patients
remained seated throughout the procedure. Blood pressure
(BP) and heart rate (HR) were recorded prior to and post-
CRH administration as well as adverse reaction during or
post-CRH infusion. The mean ± standard error of mean
(SEM) for pre- and post-CRH systolic BP was 144 ± 3.9a n d
131 ± 3.3mm/hr and the pre- and post-CRH diastolic BP
were 82.5 ± 2.5a n d8 1 .6 ± 2.5mm/hr, respectively. The pre-
and post-CRH HR were 76.9 ±1.5a n d8 2 .1 ±1.8beats/min,
respectively.
2.4.ClinicalAssessment. Onthedayofthestudy,participants
were asked to assess the extent to which they were aﬀected
by pain, fatigue, and their disease in general using 10cm
visual analogue scales (VASs), disability using the Health
Assessment Questionnaire (HAQ) score, and disease activityInternational Journal of Endocrinology 3
using the Disease Activity Score 28 (DAS28). A full clinical
history was taken, including details of disease severity and
duration, and details of all medications and other illnesses
(particularly those known to inﬂuence HPA axis regulation).
Standard clinical assessments of RA were carried out,
including swollen and tender 28 joint counts and clinician’s
overall assessment of disease using VAS and DAS28. Blood
tests for the acute phase response, C-reactive protein (CRP)
andplasmaviscosity(PV),weretakenifnotalreadyobtained
within the previous week. X-rays of the hands were taken if
not done within the previous 6 months.
2.5. Laboratory Measurements. CRP and PV analyses were
performed by the routine hospital laboratory. Salivary and
plasma cortisol were measured by radioimmunoassay in
sodiumcitrate/sodiumorthophosphatebuﬀeratpH3.Saliva
samples were diluted in buﬀer and assayed in duplicate
with radiolabelled iodine 125-cortisol and antiserum. Total
assay tube volume was 0.3mL [22]. Cortisol antiserum
is a rabbit polyclonal antibody raised against cortisol-3-
BSA (B391, Acris Antibodies, Hiddenhausen, Germany).
Cross-reactivities are prednisolone 36%, 11-deoxycortisol
10%, corticosterone 3.2%, and cortisone 0.9%. Inter- and
intraassay coeﬃcients of variation are both less than 10%.
After 24 hours incubation at 4◦C, activated charcoal was
added to each tube and tubes were centrifuged for 15
minutes. Supernatants were discarded and radioactivity in
the pellets was measured on a gamma counter [23].
2.6. Statistics. Sample size was initially set at 40 patients,
to allow for discrimination in outcomes between groups
of normal and abnormal Dex-CRH responders which, on
the basis of the pilot study, were expected to be about
50% each. Analysis was planned for after the ﬁrst 20
patients had been included to conﬁrm the anticipated ratios.
Descriptive statistics (mean and 95% conﬁdence intervals)
were calculated for patient characteristics and for plasma
cortisol at each time interval. Each CRH response was
classiﬁed as “responder” or “nonresponder” according to
the pattern observed and without knowledge of patient or
disease characteristics. Responders would be expected to
have cortisol increases greater than those shown by normal
volunteers and similar to the three “responder” patients in
our previous report [13].
3. Results
Theclinicalcharacteristicsandresultsfortheﬁrst20patients
included in the study are shown in Table 1. A list of
medication taken by the patients recruited is provided in
Table 2. Baseline plasma cortisol after oral dexamethasone
andthecortisolresponsestoCRHforeachpatientareshown
in Figure 1. Also included in Figure 1 are the mean and 95%
conﬁdence intervals (CIs) for normal controls as previously
reported [13]. Following dexamethasone administration the
previous evening, baseline plasma cortisol concentrations
were low in all the participants. There was no abnor-
mal cortisol response to CRH challenge in any patient.
Table 1: Characteristics of patients∗.
Age (years) 63.1 (10.5)
M:F 6:14
RA duration (years) 14.7 (10.8)
Tender joint count 18.4 (8.9)
Swollen joint count 7.6 (5.3)
CRP (mg/L) 25.5 (26.7)
Patients with erosions (%) 12 (60)
Patients with RF (%) 14 (70)
Pain (VAS, 0–100 mm) 51.8 (22.0)
Patient overall severity (VAS, 0–100mm) 49.3 (21.6)
Fatigue(VAS, 0–100mm) 62.2 (23.5)
Health assessment questionnaire score 1.894 (0.454)
Disease activity score (DAS28) 5.7 (1.2)
∗Mean and SD (standard deviation) unless indicated,
RA: rheumatoid arthritis, CRP: C-reactive protein,
VAS: visual analogue scale.
Table 2: Medications of the participants.
Treatment No. of patients (%)
NSAIDs 10 (50)
COX-II inhibitors 2 (10)
Methotrexate (MTX) 10 (50)
Sulphasalazine (SSZ) 2 (10)
MTX and SSZ 5 (40)
Gold 1 (5)
NSAIDs: Nonsteroidal anti-inﬂammatory drugs,
COX-II: cyclo-oxygenase II.
Although3subjectsdidmountasmallcortisolresponseeach
was within the range previously observed for healthy control
subjects, and neither approached the response expected
without dexamethasone suppression (>200ng/mL).
In those salivary samples (n = 26) which had cortisol
concentrations above the detection limit of the assay (0.2ng)
there was a positive correlation between plasma and saliva
cortisol (r = 0.876, P<. 01) (Figure 2).
4. Discussion
All 20 patients with RA showed a normal dexamethasone
suppression of cortisol at baseline and mounted no response
to the CRH challenge in contrast to the previous pilot
study, in which a subgroup of RA patients failed to show
cortisol suppression. Although 3 patients in the present
study did mount a small cortisol response each was within
the normal range, therefore we are unable to show further
evidence for a subgroup of RA patients with an abnormal
HPA axis response to the Dex-CRH test. We considered
several possible reasons for the discrepancy. Firstly, the seven
patients included in the previous pilot study were inpatients
admitted to the hospital because of a ﬂare of their RA.
Now we infrequently admit patients with severely active RA
(since the era of antitumour necrosis factor and other forms
of biologic therapy) and our participants were outpatients.4 International Journal of Endocrinology
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Figure 1: Dex-CRH Test in 20 patients. Each line shows the cortisol
values for one patient. The dotted line shows the mean and 95%
conﬁdence interval for normal subjects previously reported [13].
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Figure 2: Plasma and Salivary Cortisol. Cortisol values for simul-
taneous plasma and salivary samples where the value for salivary
cortisol was above the limit of detection.
However, they showed a wide range of disease activities
with mean DAS28 score of 4.23, and some patients had
higher disease activity than the pilot study patients. Patients
on current anti-TNF therapy were excluded, so avoiding
previously reported alterations in steroid metabolism [24,
25]. Secondly we considered the time at which the study had
been conducted. In the present study, the test was performed
in the morning while in the pilot study it was performed
in the afternoon. However the half life of dexamethasone
is greater than 36 hours, therefore patients in both studies
should have been well suppressed by the dexamethasone at
the time of the CRH infusion.
We also considered if the CRH may have been inactive.
The majority of our patients experienced “hot ﬂushes”—a
mild, short-term sensation of warmth felt in the head, neck,
andupperpartofthebodywhichisawellrecognisedeﬀectof
CRH infusion, showing that our preparation was bioactive,
also blood pressure decreased and heart rate increased
immediately after CRH. Finally we considered the possibility
that 3 of the 7 patients in the previous study did not take
their dexamethasone tablets the night of the study. In the
present study, we telephoned each patient the night before
the test to remind them about their tablets. Our results do
notex cludeHP Aaxisdysr egulation,butfurtherin v estigation
in RA may require the measurement of a wide range of
hormonal and immune responses including cytokine levels
following stressor challenge.
Although we found that no patients mounted a cortisol
response to CRH greater than the 95% conﬁdence interval
for normal healthy volunteers in our previous study [13], it
did appear that 18 out of 20 patients had lower levels than
the normal subjects in response to CRH infusion, although
due to slight diﬀerences in the protocols between studies
it was not appropriate to compare the two sets of data to
determine statistical signiﬁcance. While some studies have
reported abnormal cortisol responses to the CRH test in RA
patients, the majority have not (reviewed in [10, 26]). In the
present study we addressed the question whether diﬀerent
subsets of RA patients can be distinguished by the Dex-CRH
test and we did not design the study to examine diﬀerences
in responses to CRH between patients and healthy controls.
Therefore any such diﬀerences, if they exist, must be the
subject of a larger investigation with a diﬀerent study design
incorporating healthy participants as the controls.
Measurement of salivary cortisol is a common method to
assess HPA axis activity in RA [27–30] but to our knowledge,
this is the ﬁrst paper that has studied the correlation between
salivary and plasma cortisol in RA patients. Plasma and
salivary cortisol have been measured in a study testing
cortisol elimination from plasma in premenopausal women
with RA, where the elimination proﬁles were similar, but
correlation analysis was not reported [29]. However, some
RA patients have hyposalivation and reduced buﬀering
capacity [31–33] and 25–35% of RA patients have secondary
Sjogren’s syndrome [34, 35], which might alter the relation-
ship between plasma and salivary concentrations. We have
found a strong correlation (r = 0.876) between saliva and
plasma cortisol concentrations in those patients who have
detectable salivary cortisol. Therefore, salivary cortisol can
be used as an alternative to plasma cortisol in RA patients,
oﬀering a convenient, reliable, and non-invasive method for
cortisol measurement. If developed as a suitable home-use
kit it might avoid hospital attendance for sample collection
in studies involving RA patients.
5. Conclusion
In conclusion, in contrast to an initial pilot study, we found
no abnormalities in the Dex-CRH test in the 20 patients
with RA. These negative results are important as they are
evidence supporting HPA-axis integrity in RA. In addition,
a strong correlation between saliva and plasma cortisol
concentrations in RA suggests that salivary measurements
may oﬀer an alternative to plasma cortisol in future studies.
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